A5035579995- Drug Transport and Resistance Mechanisms
- Antibiotics Pharmacokinetics and Efficacy
- Cancer therapeutics and mechanisms
- Parkinson's Disease Mechanisms and Treatments
- Antibiotic Resistance in Bacteria
- Advancements in Transdermal Drug Delivery
- DNA and Nucleic Acid Chemistry
- Pharmacological Effects and Toxicity Studies
- Dermatology and Skin Diseases
- Contact Dermatitis and Allergies
- Botulinum Toxin and Related Neurological Disorders
- Hepatitis C virus research
- Neurological disorders and treatments
- Computational Drug Discovery Methods
- Alzheimer's disease research and treatments
- Colorectal Cancer Treatments and Studies
AC Immune (Switzerland)
2022-2023
GlaxoSmithKline (Switzerland)
2019
UCLouvain
2011-2013
Purpose: The current study aimed to compare 2 topical diclofenac products (diclofenac diethylamine [DEA] 1.16% emulsion and sodium [Na] 5% gel). quantitative evaluation of skin permeability the qualitative their physical characteristics were performed. Methods: DEA Na gel was compared in vitro using Franz diffusion cells following a single, fixed, 10 mg/cm 2, dose product applied 0.64 cm area stratum corneum surface ex vivo human samples. formulations assessed by rheological measurement...
Exposure of J774 mouse macrophages to stepwise increasing concentrations ciprofloxacin, an antibiotic inhibiting bacterial topoisomerases, selects for resistant cells that overexpress the efflux transporter Abcc4 (Marquez et al. [2009] Antimicrob. Agents Chemother. 53: 2410-2416), encoded by gene located on Chromosome 14qE4. In this study, we report genomic alterations occurring along selection process. expression progressively increased upon rounds, with exponential changes observed between...
Abstract Background Parkinson’s disease (PD) and other synucleinopathies such as Multiple System Atrophy (MSA) involve a progressive accumulation of a‐synuclein (a‐syn) inclusions that correlates with stage clinical manifestations. The development PET agent capable imaging a‐syn would significantly aid in differential diagnosis, staging, monitoring possible benefits candidate therapeutic agents targeting a‐syn. Due to the generally lower pathologic burden relative brain proteinopathies,...
Abstract Background Parkinson’s disease (PD) and other synucleinopathies, such as Multiple System Atrophy (MSA), involve a progressive accumulation of a‐synuclein (a‐syn) inclusions which correlate well with clinical manifestations. A PET agent capable imaging specifically selectively a‐syn could significantly improve differential diagnosis trials for drug candidates targeting a‐syn. Here, we report the preclinical initial characterization [ 18 F]ACI‐12589 in patients different...